ZTS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 28.42% compared to Zoetis's net margin of 21.68%. Zoetis's return on equity of 51.03% beat Eli Lilly and's return on equity of 78.25%.

Zoetis has a consensus price target of $194.12, signalling upside risk potential of 21.88%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Eli Lilly and has higher upside potential than Zoetis, analysts believe Eli Lilly and is more attractive than Zoetis.

Zoetis has a beta of 0.942, which suggesting that the stock is 5.835% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.17%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Zoetis pays 31.62% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Zoetis's net income of $631M is lower than Eli Lilly and's net income of $2.8B. Notably, Zoetis's price-to-earnings ratio is 28.59x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.76x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 28.42% compared to Zoetis's net margin of 32.71%. Zoetis's return on equity of 51.03% beat Merck &'s return on equity of 39.02%.

Zoetis has a consensus price target of $194.12, signalling upside risk potential of 21.88%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 38.24%. Given that Merck & has higher upside potential than Zoetis, analysts believe Merck & is more attractive than Zoetis.

Zoetis has a beta of 0.942, which suggesting that the stock is 5.835% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.17%. Merck & offers a yield of 4.16% to investors and pays a quarterly dividend of $0.81 per share. Zoetis pays 31.62% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are smaller than Merck & quarterly revenues of $15.5B. Zoetis's net income of $631M is lower than Merck &'s net income of $5.1B. Notably, Zoetis's price-to-earnings ratio is 28.59x while Merck &'s PE ratio is 11.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.76x versus 3.02x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 28.42% compared to Zoetis's net margin of 21.63%. Zoetis's return on equity of 51.03% beat Pfizer's return on equity of 8.72%.

Zoetis has a consensus price target of $194.12, signalling upside risk potential of 21.88%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Pfizer has higher upside potential than Zoetis, analysts believe Pfizer is more attractive than Zoetis.

Zoetis has a beta of 0.942, which suggesting that the stock is 5.835% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.17%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Zoetis pays 31.62% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Zoetis quarterly revenues are $2.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Zoetis's net income of $631M is lower than Pfizer's net income of $3B. Notably, Zoetis's price-to-earnings ratio is 28.59x while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.76x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 28.42% compared to Zoetis's net margin of -7.89%. Zoetis's return on equity of 51.03% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Zoetis has a consensus price target of $194.12, signalling upside risk potential of 21.88%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 22.4%. Given that Supernus Pharmaceuticals has higher upside potential than Zoetis, analysts believe Supernus Pharmaceuticals is more attractive than Zoetis.

Zoetis has a beta of 0.942, which suggesting that the stock is 5.835% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.408%.

Zoetis has a quarterly dividend of $0.50 per share corresponding to a yield of 1.17%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 31.62% of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.2B, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Zoetis's net income of $631M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Zoetis's price-to-earnings ratio is 28.59x while Supernus Pharmaceuticals's PE ratio is 28.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 7.76x versus 2.66x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.